GeoVax Labs (GOVX) Non-Current Assets (2010 - 2026)
GeoVax Labs (GOVX) posted quarterly Non-Current Assets of $467458.0 for Q2 2026, up 117.55% year-over-year from $214872.0 in Q2 2025, and down 54.49% quarter-over-quarter from $1.0 million in Q4 2025.
GeoVax Labs (GOVX) Non-Current Assets (2010 - 2026) Analysis & Trends
GeoVax Labs (GOVX) has reported Non-Current Assets for 17 consecutive years, with $467458.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Assets rose 117.55% year-over-year to $467458.0; the TTM figure through Jun 2026 stood at $1.9 million (up 113.86% YoY), while the FY2025 annual figure was $1.0 million, up 364.84% from the prior year.
- Non-Current Assets slipped to $467458.0 in Q2 2026 per GOVX's latest filing, from $1.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $2.4 million in Q3 2022 and bottomed at $214007.0 in Q3 2025.
- Historically, Non-Current Assets has averaged $897268.3 across 5 years, with a median of $495804.0 in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 1334.49% — and 2024, when it slumped 84.19%.
- GeoVax Labs' Non-Current Assets stood at $2.4 million in 2022, then slumped by 41.99% to $1.4 million in 2023, then plunged by 84.19% to $220984.0 in 2024, then jumped by 364.84% to $1.0 million in 2025, then plunged by 54.49% to $467458.0 in 2026.
- Business Quant data shows GOVX's Non-Current Assets at $467458.0 in Q2 2026, $1.0 million in Q4 2025, and $214007.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.59 Bn | 131.73 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.21 Bn | 78.22 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.65 Bn | 60.47 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 18.06 Bn |
| 10 | GeoVax Labs | 2.92 Mn | -220,776.39 | - | 467,458.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 467,458.00 |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 214,007.00 |
| Jun 30, 2025 | 214,872.00 |
| Mar 31, 2025 | 220,957.00 |
| Dec 31, 2024 | 220,984.00 |
| Sep 30, 2024 | 242,625.00 |
| Jun 30, 2024 | 251,547.00 |
| Mar 31, 2024 | 495,804.00 |
| Dec 31, 2023 | 1.40 Mn |
| Sep 30, 2023 | 1.40 Mn |
| Jun 30, 2023 | 1.42 Mn |
| Mar 31, 2023 | 1.42 Mn |
| Dec 31, 2022 | 2.41 Mn |
| Sep 30, 2022 | 2.43 Mn |
| Jun 30, 2022 | 1.20 Mn |
| Mar 31, 2022 | 217,865.00 |
| Dec 31, 2021 | 167,948.00 |
| Sep 30, 2021 | 179,663.00 |
| Jun 30, 2021 | 160,809.00 |